Anesthesiology
Review Panel
- CardiovascularReview Panel
- ChemistryReview Panel
- DentalReview Panel
- Ear, Nose, ThroatReview Panel
- Gastroenterology and UrologyReview Panel
- General HospitalReview Panel
- HematologyReview Panel
- ImmunologyReview Panel
- MicrobiologyReview Panel
- NeurologyReview Panel
- MiscellaneousMiscellaneous
- Subpart B—Cardiovascular Diagnostic DevicesCFR Sub-Part
- Subpart B—Diagnostic DevicesCFR Sub-Part
- Subpart B—Neurological Diagnostic DevicesCFR Sub-Part
- Subpart B—Physical Medicine Diagnostic DevicesCFR Sub-Part
- Subpart C—Cardiovascular Monitoring DevicesCFR Sub-Part
- Subpart D—Physical Medicine Prosthetic DevicesCFR Sub-Part
- PHLPowered Exoskeleton2Product Code
- K241822ReWalk® 7 Personal Exoskeleton (50-20-0005)2Cleared 510(K)
- K233695Medical HAL Lower Limb Type (HAL-ML)2Cleared 510(K)
- K232077Atalante X2Cleared 510(K)
- K221696ReWalk P6.02Cleared 510(K)
- K221859Atalante2Cleared 510(K)
- K220988EksoNR2Cleared 510(K)
- K213452GEMS-H2Cleared 510(K)
- K201473ExoAtlet-II2Cleared 510(K)
- K201559HAL for Medical Use(Lower Limb type)2Cleared 510(K)
- K201539Keeogo Dermoskeleton System2Cleared 510(K)
Show All 23 Submissions
- Subpart E—Neurological Surgical DevicesCFR Sub-Part
- Subpart E—Surgical DevicesCFR Sub-Part
- Subpart F—Cardiovascular Therapeutic DevicesCFR Sub-Part
- Subpart F—Neurological Therapeutic DevicesCFR Sub-Part
- Subpart F—Physical Medicine Therapeutic DevicesCFR Sub-Part
- Subpart F—Therapeutic DevicesCFR Sub-Part
- Obstetrical and GynecologicalReview Panel
- OphthalmicReview Panel
- OrthopedicReview Panel
- PathologyReview Panel
- Physical MedicineReview Panel
- RadiologyReview Panel
- General and Plastic SurgeryReview Panel
- ToxicologyReview Panel
- Medical GeneticsReview Panel
- UnknownReview Panel
ReWalk® 7 Personal Exoskeleton (50-20-0005)
- Page Type
- Cleared 510(K)
- FDA Hosted PDF* The FDA doesn't provide PDFs for all submissions.
- 510(k) Number
- K241822
- 510(k) Type
- Traditional
- Applicant
- ReWalk Robotics Ltd. DBA Lifeward
- Country
- Israel
- FDA Decision
- Substantially Equivalent
- Decision Date
- 3/12/2025
- Days to Decision
- 261 days
- Submission Type
- Summary